Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials

Date: 
June, 2017

June 26, 2017. Several novel type 2 diabetes (T2D) medications have recently shown promise in preventing cardiovascular (CV) disease. This review discusses the results of 4 recent randomized controlled trials of empagliflozin, pioglitazone, liraglutide, and semaglutide in preventing CV outcomes in patients with or at risk of T2D and with established CV disease. On the basis of these trials, the authors propose a paradigm shift in T2D management, particularly for patients with prior macrovascular disease. This would involve a transition from current algorithms based primarily on A1C values to a more comprehensive strategy that also focuses on CV disease prevention. Click here for full article